Actio Biosciences, Inc.’s Post

Well I guess double congratulations are in order for the Esperion team! Hot off the press the FDA have approved the following The bempedoic acid component of NEXLIZET and NEXLETOL is indicated to reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with: established cardiovascular disease (CVD), or at high risk for a CVD event but without established CVD. As an adjunct to diet: NEXLIZET, alone or in combination with other LDL-C lowering therapies, to reduce LDL-C in adults with primary hyperlipidemia, including HeFH. NEXLETOL, in combination with other LDL-C lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with primary hyperlipidemia, including HeFH. Bravo.

Lilly’s donanemab was approved recently by the US FDA for early symptomatic Alzheimer’s disease. Looking forward to longer-term data in real-world settings and results from ongoing trial with Lilly’s another potential amyloid-targeting therapeutic for Alzheimer’s disease, remternetug. Here is an interesting short read on donanemab’s target - https://lnkd.in/dQPt-_Re

New Indication for Bempedoic Acid (Nexletol) https://bit.ly/4aYMp4d The oral adenosine triphosphate-citrate lyase (ACL) inhibitor bempedoic acid was approved by the FDA in 2020 for use alone (Nexletol – Esperion) and in a fixed-dose combination with the cholesterol absorption inhibitor ezetimibe (Nexlizet) as an adjunct to maximally tolerated statin therapy in adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional LDL-cholesterol (LDL-C) lowering. The indication has now been expanded to include reducing the risk of myocardial infarction (MI) and coronary revascularization in adults with established cardiovascular disease (CVD) or at high risk for a CVD event who are unable to take recommended statin therapy.

👉Evolution of More Aggressive LDL-Cholesterol Targets and Therapies for Cardiovascular Disease Prevention ☝️More recent trials have further demonstrated the impact of non-statin therapies, including ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors, and, most recently, bempedoic acid, on reducing ASCVD outcomes. The availability of these and other newer therapies has prompted clinicians to strive for lower LDL-C targets to address residual ASCVD risk after statin therapy. This paper will provide an overview of the historical trends in lipid management and therapeutics and review the current state of evidence for lower LDL-C targets in clinical guidelines and recommendations. 🔓Open access https://lnkd.in/dSaPrBbf

9 out of 10 patients are not aware that they have chronic kidney disease, this is when your kidneys cannot filter your blood properly. In the early stages of the disease, most people do not have symptoms. If left untreated, kidney disease can progress to kidney failure and early cardiovascular disease. Consult your Doctor to know your risk, get tested regularly and take medication as directed #Algorithm #LifeInFocus #Pharmaceuticals Kidney disease: the basics. Retrieved from https://lnkd.in/gTvbJUwf

Novartis Reveals the P-IIIb (V-INITIATE) Trial Results of Leqvio for Treating Atherosclerotic Cardiovascular Disease (ASCVD) #novartis #leqvio #atheroscleroticcardiovasculardisease #clinicaltrial #phase3b #safety #efficacy #treatment #vinitiate #orion3 #orion8

Inclisiran is a gene-based injectable drug, administered every 6 months, to lower LDL-cholesterol. It is approved for use in adults with #hypercholesterolaemia or atherosclerotic cardiovascular disease, or who are at high risk of #cardiovascular disease. It is an alternative treatment option (or can be used in combination with) other lipid-lowering medicines for patients on a maximum tolerated dose of a statin or who are statin intolerant. Read the review: https://lnkd.in/gRxra387

First Randomized Controlled Trial Showing Non-Pharma Intervention (Lifestyle Changes) Can Help Reduce Alzheimer’s Disease SymptomsFirst Randomized Controlled Trial Showing Non-Pharma Intervention (Lifestyle Changes) Can Help Reduce Alzheimer’s Disease Symptoms https://lnkd.in/e38a5Wdy

Register today and join me for the Primary Care Diabetes Society of Australia Conference 👉 https://lnkd.in/gDgYfX6M I'm really excited for Daniel Fineberg's session at #PCDSA24 where he'll deep dive into the cardiometabolic drugs that make a real difference in diabetes care and the emerging role of PCSK9 inhibitors and SGLT2i in diabetes complication management. He'll also explore the management of fatty liver disease – what is the issue, who to screen, how to screen and what to do about it!

Semaglutide Reduces Risk Of Serious Kidney Outcomes, Major Cardiovascular Events And Death In People With Type 2 Diabetes And Chronic Kidney Disease, Study Finds CNN (5/24, McPhillips) reported, “Weekly injections of semaglutide medications like Ozempic significantly reduce the risk of serious kidney outcomes, major cardiovascular events and death among people who have type 2 diabetes and chronic kidney disease, according to a new study.” These outcomes “occurred 331 times among trial participants who were treated with semaglutide, compared with 410 events among those who received the placebo.” And “when scaled by the number of years each person was in the trial, there were 5.8 events for every 100 years of follow-up among those taking semaglutide, compared with 7.5 events for every 100 years of follow-up among those who received the placebo.” The results were presented at the European Renal Association Congress and published in the New England Journal of Medicine.